Identification of New Leads for the Indazole-Based LRRK2 Inhibitors

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2024; 20(12): 1324
DOI: 10.1055/a-2439-6858

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Seong Heon Kim (Hyundai Pharm)

LRRK2 - Parkinson’s disease - indazoles - BCRP - bioisosteres - CNS drug-likeness

Article published online:
21 November 2024

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany